VIA
LXRX icon

Virtus Investment Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Virtus Investment Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$409K Buy
+170,415
New +$332K 0.1% 266
2025
Q2 		– Sell
-436,672
Closed -$201K – 473
2025
Q1 		$201K Buy
+436,672
New +$275K 0.05% 264

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Virtus Investment Advisers's LXRX Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 170,415 shares worth $409K. The stake represents 0.1% of the portfolio and ranks #266 among its holdings. This is a return to the name: Virtus Investment Advisers previously reported a position in LXRX as recently as Q1 2025.

Virtus Investment Advisers first reported a position in LXRX in Q1 2025 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Virtus Investment Advisers held 170,415 shares of Lexicon Pharmaceuticals worth $409K as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Virtus Investment Advisers position in Q2 2026.
  • Lexicon Pharmaceuticals made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #266 holding.
  • Virtus Investment Advisers first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.